Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Projected copays under standard Part D cost-sharing are approximately $50/month for eligible beneficiaries - primarily adults 65 and older, along with certain younger individuals with qualifying disabilities or end-stage renal disease
Each serving is packed with essential nutrients like Magnesium Malate, known for its ability to ease muscle pain and tension, and Boswellia Serrata to combat inflammation
Mechanisms, FDA status, US law, and IGF-1
New to GLP-1s Currently taking GLP-1s 2 month starter programs *Special offer pricing only available to new customers Featured product Compounded Tirzepatide GLP-1/GIP injections $149/mo $299 for 2 months Compounded Semaglutide GLP-1 injections $74/mo $149 for 2 months Brand name monthly plans Wegovy (GLP-1 pen) $1,839 Zepbound (GLP-1/GIP pen) $1,498 2 month special offer *Special offer pricing only available to new customers Featured product Compounded Tirzepatide GLP-1/GIP injections $224/mo $449 for 2 months Compounded Semaglutide GLP-1 injections $112/mo $224 for 2 months Monthly plans Compounded Tirzepatide GLP-1 injections $299 Compounded Semaglutide GLP-1 injections $149 Wegovy (GLP-1 pen) $1,839 Zepbound (GLP-1/GIP pen) $1,498 2 month starter programs *Special offer pricing only available to new customers Featured product Compounded Tirzepatide GLP-1/GIP injections $149/mo $299 for 2 months Compounded Semaglutide GLP-1 injections $74/mo $149 for 2 months 2 month special offer *Special offer pricing only available to new customers Featured product Compounded Tirzepatide GLP-1/GIP injections $224/mo $449 for 2 months Compounded Semaglutide GLP-1 injections $112/mo $224 for 2 months Monthly plans Compounded Tirzepatide GLP-1 injections $299 Compounded Semaglutide GLP-1 injections $149 Brand name monthly plans Wegovy (GLP-1 pen) $1,839 Zepbound (GLP-1/GIP pen) $1,498 Get $3,700 of support for FREE when you buy with us Get more than just meds
TRANSCEND-T2D-1 detailed results are scheduled for the American Diabetes Association Scientific Sessions in June 2026
